On September 23, 2019 Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) reported that data on the ability of DRP to predict response to 5-FU anti-cancer treatment in late-stage colorectal cancer will be presented at the annual congress of European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) in Barcelona (Press release, Oncology Venture, SEP 23, 2019, View Source [SID1234539706]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Fluorouracil (5-FU) is a central component of the standard of care in colorectal cancer treatment. Unfortunately, not all patients benefit from 5-FU, and individual risk assessment is needed to optimize the therapy for individual patients.
Oncology Venture is developing its first-in-class Drug Response Prediction (DRP) technology by utilizing Artificial Intelligence (AI) proprietary algorithms. It has previously been demonstrated that DRP can predict which patients will benefit from 5-FU when administered after surgery in the adjuvant setting. A new study now shows that the use of DRP can be successfully expanded to patients with late-stage, metastasized colorectal cancer. This by using the biopsy material obtained when the patient was initially diagnosed.
This data is presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) annual cancer congress in Barcelona September on 27 September – 1 October, 2019 as an abstract with the title "Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer, and as a poster (please see below).
Poster Display session 2 (ID 211)
Date: 29.09.2019
Time: 12:00 – 13:00
Location: Poster Area (Hall 4)
For further information, please contact:
For investor inquiries
Ulla Hald Buhl, IR & Communication
E-mail: [email protected]
Telephone +45 21 70 10 49
For media inquiries
Thomas Pedersen, Carrotize PR & Communications
E-mail: [email protected]
Telephone +45 60 62 93 90